Compare Krispy Kreme Inc (DNUT) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Krispy Kreme Inc vs Novo Nordisk A/S — how do they compare? Krispy Kreme Inc trades at $2.96 (market cap $521.37M), while Novo Nordisk A/S trades at $38.51 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 317.1× Krispy Kreme Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Krispy Kreme Inc for 45 Days and Novo Nordisk A/S for 116 Days on average.
| DNUT | NVO | |
|---|---|---|
Market Cap | $521.37M | $165.31B |
Volume | 2,293,015 | 11,432,838 |
Sector | Consumer Staples | Health |
52-Week High | $4.70 | $63.98 |
52-Week Low | $2.87 | $35.29 |
Typical Hold Time | 45 Days | 116 Days |
Enterprise Value | $1.76B | $179.56B |
Dividend Yield | 3.47% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $2.92, down 3.31% today, amid bearish technical signals and negative profitability. The company reported a significant net loss of $515.77M in 2025 despite $1.52B revenue, with negative margins and declining cash flow from operations. Recent news highlights ongoing legal investigations into fiduciary duties of officers and directors, creating investor uncertainty alongside seasonal product launches.
The outlook remains challenged by persistent losses and high debt levels, though analyst consensus leans bullish with 50% buy ratings. Key risks include legal overhangs, competitive pressure, and execution on profitability. Valuation metrics show mixed signals with low P/S but negative earnings, requiring careful monitoring of turnaround efforts and legal developments.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
